Article Details

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to ...

Retrieved on: 2021-04-27 12:33:45

Tags for this article:

Click the tags to see associated articles and topics

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to .... View article details on HISWAI: https://pipelinereview.com/index.php/2021042778021/Antibodies/OSE-Immunotherapeutics-and-Veloxis-Pharmaceuticals-Enter-Into-Global-License-Agreement-to-Develop-Manufacture-and-Commercialize-FR104-a-CD28-Antagonist-in-the-Organ-Transplant.html

Excerpt

... rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up